Skip to content

Nasal microbiota and swine respiratory diseases

Specialized Group:

Virginia Aragón, Miguel Blanco, Florencia Correa-Fiz, Mar Costa-Hurtado, Nuria Galofré-Milà, Eva Huerta, Yasser Mahmmond, Carlos Neila, Marina Sibila

Animal Health Research Center (CReSA) and Agri-Food Research and Technology Institute (IRTA), Campus of the Autonomous University of Barcelona, ​​08193 Bellaterra, Barcelona, ​​Spain

virginia.aragon@irta.cat

Group photo. From left to right, Yasser Mahmmod, Miguel Blanco, Pau Obregón, Virginia Aragón, Berenice Plasencia, Flor Correa, Carlos Neila, Sergi López, Marina Sibila, Nuria Galofré, Eva Huerta and Mar Costa

There is great pressure to reduce the use of antimicrobials, due to the constant increase in resistance and the imminent problem for the health of animals and people. In Spain, work is being done through a national plan, the PRAN, and, although the use of antimicrobials is still high, it is worth noting the drastic reduction of 97% in the use of colistin in pigs between 2015 and 2018. In pig production , respiratory diseases represent one of the biggest health problems and consequently are one of the main causes of antimicrobial use in this sector.

One of the respiratory pathogens of importance in the pig sector is Haemophilus parasuis, which causes Glässer's disease (fibrinous polyserositis, including meningitis and arthritis). For years our group has focused on studying the pathogenicity of this bacterium with the ultimate goal of developing an effective vaccine. Through genetic typing studies, virulence assays and experimental infections in piglets, we defined different degrees of virulence in field strains and detected a group of molecules associated with said virulence, the trimeric VtaA autotransporters. VtaAs are antigenic proteins located on the outer membrane, which are expressed during pig infection. VtaAs are virulence factors, involved in mechanisms such as adhesion to extracellular matrix proteins or resistance to phagocytosis. The analysis of its structure allowed us to define an epitope exposed on the bacterial surface, common to all the VtaA of the virulent strains. Antibodies against this epitope are opsonizing and would allow directing the response specifically to virulent strains. In addition, since the epitope is present in all VtaAs associated with virulence, antigenic exchange would be avoided (“antigenic switching”) between different VtaAs.

In recent years our interest has expanded to other porcine pathogens, such as Mycoplasma hyorhinis and Streptococcus suis, and the role of the nasal microbiota. The nasal cavity is the natural entry route for respiratory pathogens, and there they encounter the first barrier against infection, the nasal microbiota. Comparing this microbiota in piglets from farms with Glässer's disease versus that of healthy piglets allowed us to determine that the nasal microbiota can predispose piglets to disease. We note that several bacterial taxa, such as Bacteroidales, Lactobacillales and Clostridiales, were reduced in the nasal microbiota in weaned piglets that later developed Glässer's disease. Glässer's disease is caused by virulent strains of H.parasuis, but this bacterium also has non-virulent strains, which can protect against the disease. The microbiota associated with these two types of strains of H parasuis turned out to be different, detecting some bacterial families that could facilitate the colonization of virulent strains of H.parasuis (and therefore increase the risk of disease), and others that could facilitate the colonization of non-virulent strains (and therefore promote protection against Glässer's disease). These findings support the idea that specific interventions can be designed to achieve an adequate microbiota composition to ensure piglet protection. But the role of the nasal microbiota is not specific to Glässer's disease, and piglets that later developed polyserositis due to M. hyorhinis they had a very different composition to that of piglets from healthy farms, with different bacterial genera associated with health and disease.

Additionally, antimicrobials can have side effects on the beneficial microbiota. We have recently shown that the elimination of perinatal antimicrobial treatments produces an increase in bacterial diversity in the nasal microbiota. This increase in diversity has long-term beneficial effects, with a reduction in mortality and medication costs, and an increase in productivity. The most significant changes in the composition of the microbiota upon removal of antimicrobials were an increase in Prevotella and Lactobacillus, and a reduction of Moraxella and Bergeyella (Figure 1).

Figure 1. Principal coordinates (PC) analysis showing the beta diversity of the nasal microbiota of weaning piglets (3-4 weeks of age) before (red dots) and after (green dots) the removal of perinatal antimicrobial treatments. The gray spheres indicate the 5 most abundant genera and are proportional to their relative abundance.

Our group also has experience in other respiratory pathogens of great economic importance worldwide, such as Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae, causal agents of pneumonia and pleuropneumonia in pigs. It is worth highlighting the fine-tuning of pig disease models, which are very useful for studies of new therapeutic products, vaccines or for the validation of diagnostic tools. In addition, it has been determined that the diagnosis of M. hyopneumoniae improvement using laryngeal swabs in live animals and lower respiratory tract samples (brochoalveolar lavage or lung swab) in dead animals, and methods of quantifying lung lesions have been established for both pathogens.

Our future objective will continue to be the control of swine respiratory diseases in the absence of antibiotics, with special emphasis on alternative strategies, such as the development of probiotics.

 

Representative Publications

Betlach AM, Maes D, Garza-Moreno L, Tamiozzo P, Sibila M, Haesebrouck F, Segalés J, Pieters M. (2019). Mycoplasma hyopneumoniae variability: Current trends and proposed terminology for genomic classification. Transbound Emerg Dis 66:1840-54.

Costa-Hurtado M, Garcia-Rodriguez L, Lopez-Serrano S and Aragon V. Abushattal S, Vences A, Dos Santos NMS, Do Vale A and Osorio CR. Haemophilus parasuis VtaA2 is involved in adhesion to extracellular proteins. Vet Res 50:69.

Correa-Fiz F, Gonçalves Dos Santos JM, Illas F and Aragon V. (2019). Antimicrobial removal on piglets promotes health and higher bacterial diversity in the nasal microbiota. Sci Rep 9:6545.

Garza-Moreno L, Segalés J, Aragón V, Correa-Fiz F, Pieters M, Carmona M, Krejci R and Sibila M. (2019). Characterization of Mycoplasma hyopneumoniae strains in vaccinated and non-vaccinated pigs from Spanish slaughterhouses. Vet Microbiol 231:18-23.

Garcia-Morante B, Dors A, León-Kempis R, Pérez de Rozas A, Segalés J, Sibila M. (2018) Assessment of the in vitro growing dynamics and kinetics of the non-pathogenic J and pathogenic 11 and 232 Mycoplasma hyopneumoniae strains. Vet Res 49:45.

Fernández-Aguilar X, Gottschalk M, Aragon V, Càmara J, Ardanuy C, Velarde R, Galofré-Milà N, Castillo-Contreras R, López-Olvera JR, Mentaberre G, Colom-Cadena A, Lavín S and Cabezón O. (2018). Urban Wild Boars and Risk for Zoonotic Streptococcus suis, Spain. Emerg Infect Dis 24(6):1083-6.

Mathieu-Denoncourt A, Letendre C, Auger JP, Segura M, Aragon V, Lacouture S y Gottschalk M. (2018). Limited interactions between Streptococcus suis and Haemophilus parasuis in in vitro co-infection studies. Pathogens 7(1). pii: E7.

Howell KJ, Weinert LA, Peters SE, Wang J, Hernandez-Garcia J, Chaudhuri RR, Luan SL, Angen Ø, Aragon V, Williamson SM, Langford PR, Rycroft AN, Wren BW, Maskell DJ y Tucker AW. (2017). “Pathotyping” Multiplex PCR Assay for Haemophilus parasuis: a Tool for Prediction of Virulence. J Clin Microbiol 55:2617-28.

Correa-Fiz F, Galofre-Mila N, Costa-Hurtado M and Aragon V. (2017). Identification of a surface epitope specific of virulent strains of Haemophilus parasuis. Vet Microbiol 198:116-20.

Correa-Fiz F, Fraile L and Aragon V. (2016). Piglet nasal microbiota at weaning may influence the development of Glässer’s disease during the rearing period. BMC Genomics 17:404.

Play Video

Privacy Policy

This website is owned by the SPANISH SOCIETY OF MICROBIOLOGY, whose identification data are the following:

  • Center for Biological Research (CIB-CSIC)
  • c / Ramiro de Maeztu, 9 28040 Madrid.
  • Phone. 91 561 33 81 - Fax. 91 561 32 99
  • National Registry of Associations with the national number 579
  • CIF: G28648871

1. INFORMATION AND CONSENT.

By accepting this Privacy Policy, the User is informed and gives their free, informed, specific and unequivocal consent so that the personal data provided through this website (hereinafter, the "Website") are processed by SEM.

2. OBLIGATORY TO PROVIDE THE DATA.

The data requested in the web forms are generally mandatory (unless otherwise specified in the required field) to fulfill the established purposes. Therefore, if they are not provided or are not provided correctly, they will not be able to be attended to, without prejudice to the fact that you can freely view the content of the Website.

3. FOR WHAT PURPOSE WILL THE USER'S PERSONAL DATA BE PROCESSED AND FOR HOW LONG?

The personal data provided through the Website will be processed by SEM in accordance with the following purposes:

  • Manage and process the registration requests of new members, from the "new members" forms, as well as manage the fees and derived charges.
  • Periodically send members, including by electronic means, information, events or news that may be of interest to them, if the future member gives their consent by checking the corresponding check box, or, where appropriate, opposes or revokes their consent.

4. WHAT USER DATA WILL BE PROCESSED?

SEM will process the following categories of User data:

  • Identification data: name, surname and ID.
  • Contact information: postal address, email address and telephone.
  • Professional data: workplace and professional contact details.
  • Academic data: degree and specialization.
  • Billing information.

5. WHAT IS THE LEGITIMATION OF THE PROCESSING OF USER DATA?

The treatment of the User's data by the SEM is based on the consent that is requested and that you can withdraw at any time. However, in case of withdrawing your consent, this will not affect the legality of the treatments carried out previously.
The consents obtained for the aforementioned purposes are independent so that the User may revoke only one of them, not affecting the others.

6. TO WHICH RECIPIENTS WILL THE USER DATA BE COMMUNICATED?

The data of the partners may be communicated to the following companies in the cases indicated:

• To the corresponding banking entities in order to manage the collection of direct debit bills.

The User's data will not be communicated to any other entity, except legal obligation.

7. RESPONSIBILITY OF THE USER.

The User and the Candidate for membership:
- Guarantees that you are over 18 years of age and that the data you provide to the SEM is true, accurate, complete and updated. For these purposes, the User is responsible for the veracity of all the data that he communicates and will keep the information provided suitably updated, in such a way that it responds to his real situation.
- You will be responsible for the false or inaccurate information that you provide through the Website and for the direct or indirect damages that this causes to the SEM or to third parties.

8. COMMUNICATIONS.

One of the purposes for which the SEM processes the personal data provided by Users is to send them electronic communications with information related to congresses and other events, grant programs, scientific dissemination, awards or relevant news for the recipients.
In the event that the recipient wishes to stop receiving informative communications from the SEM, they can request the cancellation of the service by sending an email to secretaria.sem@semicrobiologia.com or by clicking on the "unsubscribe" link included in the communications.

9. EXERCISE OF RIGHTS.

The User can send a letter at any time and free of charge to the SEM, Centro de Investigaciones Biológicas (CIB-CSIC) - c / Ramiro de Maeztu, 9 28040 Madrid, attaching a photocopy of their identity document, to request their rights of access, rectification, deletion, opposition, limitation, portability of your data.
You can also complain to the Spanish Agency for Data Protection, through the following address: Spanish Agency for Data Protection, C / Jorge Juan, 6, 28001-Madrid, when the interested party considers that the SEM has violated the rights that They are recognized by the applicable regulations on data protection.

10. SECURITY MEASURES.

The SEM will treat the data of Users, Candidates and Partners at all times in an absolutely confidential manner and keeping the mandatory duty of secrecy regarding them, in accordance with the provisions of the applicable regulations, adopting technical measures and measures for this purpose. necessary organizational measures that guarantee the security of your data and prevent its alteration, loss, treatment or unauthorized access, taking into account the state of technology, the nature of the stored data and the risks to which they are exposed.

Request enrollment in the course Nasal microbiota and swine respiratory diseases